HK1168051A1 - Magnetic nanoparticles - Google Patents
Magnetic nanoparticlesInfo
- Publication number
- HK1168051A1 HK1168051A1 HK12109012.1A HK12109012A HK1168051A1 HK 1168051 A1 HK1168051 A1 HK 1168051A1 HK 12109012 A HK12109012 A HK 12109012A HK 1168051 A1 HK1168051 A1 HK 1168051A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- magnetic nanoparticles
- immobilising
- clusters
- ligands
- ligand
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1845—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carbohydrate (monosaccharides, discacharides)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
- A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Inorganic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Soft Magnetic Materials (AREA)
- Hard Magnetic Materials (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Paints Or Removers (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0313259.4A GB0313259D0 (en) | 2003-06-09 | 2003-06-09 | Magnetic nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1168051A1 true HK1168051A1 (en) | 2012-12-21 |
Family
ID=27589724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12109012.1A HK1168051A1 (en) | 2003-06-09 | 2012-09-13 | Magnetic nanoparticles |
Country Status (12)
Country | Link |
---|---|
US (2) | US8557607B2 (ja) |
EP (3) | EP2277548B1 (ja) |
JP (1) | JP5008977B2 (ja) |
AT (1) | ATE487496T1 (ja) |
AU (1) | AU2004244811B9 (ja) |
CA (1) | CA2528460C (ja) |
DE (1) | DE602004030003D1 (ja) |
DK (1) | DK1631318T3 (ja) |
ES (3) | ES2401957T3 (ja) |
GB (1) | GB0313259D0 (ja) |
HK (1) | HK1168051A1 (ja) |
WO (1) | WO2004108165A2 (ja) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
US20080213177A1 (en) * | 2004-05-24 | 2008-09-04 | Thomas William Rademacher | Nanoparticles Comprising Rna Ligands |
JP3912391B2 (ja) * | 2004-05-26 | 2007-05-09 | ソニー株式会社 | 金属磁性ナノ粒子群及びその製造方法 |
KR100604976B1 (ko) * | 2004-09-03 | 2006-07-28 | 학교법인연세대학교 | 다작용기 리간드로 안정화된 수용성 나노입자 |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
CA2617869C (en) * | 2005-08-04 | 2017-02-14 | Thomas William Rademacher | Nanoparticles comprising antibacterial ligands |
DE102005042768A1 (de) | 2005-09-08 | 2007-03-15 | Ludwig-Maximilian-Universität | Magnetfeld-gesteuerter Wirkstofftransfer für die Aerosoltherapie |
CN1772303A (zh) * | 2005-10-25 | 2006-05-17 | 朱宏 | 恶性肿瘤磁热疗用纳米磁粉-抗体靶向药物 |
KR100713745B1 (ko) * | 2006-02-27 | 2007-05-07 | 연세대학교 산학협력단 | 상전이 리간드로 코팅된 수용성 자성 또는 금속 산화물나노입자 및 이의 제조방법 |
JP2007269770A (ja) * | 2006-03-09 | 2007-10-18 | Mitsubishi Chemicals Corp | 機能性磁気超ナノ微粒子及びその用途 |
AU2007242572B2 (en) * | 2006-04-13 | 2011-11-24 | Midatech Limited | Nanoparticles containing three various ligands for providing immune responses against infectious agents |
KR100803213B1 (ko) * | 2006-06-27 | 2008-02-14 | 삼성전자주식회사 | 패턴된 자기기록매체 및 그 제조방법 |
EP2099496A2 (en) * | 2006-12-08 | 2009-09-16 | Massachusetts Institute of Technology | Delivery of nanoparticles and/or agents to cells |
US9239329B2 (en) | 2006-12-18 | 2016-01-19 | Japan Science And Technology Agency | Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods |
EP2124715A2 (en) * | 2007-01-24 | 2009-12-02 | Koninklijke Philips Electronics N.V. | Method for influencing and/or detecting magnetic particles in a region of action, magnetic particles and the use of magnetic particles |
WO2008098248A2 (en) | 2007-02-09 | 2008-08-14 | Northwestern University | Particles for detecting intracellular targets |
AT503845B1 (de) * | 2007-04-11 | 2008-03-15 | Arc Austrian Res Centers Gmbh | Optische messverfahren zur molekularen detektion anhand von relaxationsmessungen in optisch anisotropen nanopartikeln |
WO2009017525A2 (en) * | 2007-04-27 | 2009-02-05 | Regents Of The University Of California | Superparamagnetic colloidal nanocrystal structures |
CA3055145A1 (en) | 2007-05-30 | 2008-12-11 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US8409463B1 (en) | 2007-07-16 | 2013-04-02 | University Of Central Florida Research Foundation, Inc. | Aqueous method for making magnetic iron oxide nanoparticles |
ES2320837B1 (es) | 2007-07-26 | 2010-03-04 | Consejo Superior De Investigaciones Cientificas | Dispositivo de hipertermia y su utilizacion con nanoparticulas. |
DE102007036570A1 (de) * | 2007-08-03 | 2009-02-19 | Siemens Ag | Screeningtest zur Erkennung von Prostataerkrankungen sowie Vorrichtung und Diagnosesubstanz zur Durchführung des Tests |
US9175015B2 (en) * | 2007-08-22 | 2015-11-03 | Colorado School Of Mines | Gold nanoparticle conjugates and uses thereof |
US9057094B1 (en) | 2007-10-25 | 2015-06-16 | University Of Central Florida Research Foundation, Inc. | Nanoparticle-mediated methods for antimicrobial susceptibility testing of bacteria |
US9107858B2 (en) * | 2007-12-05 | 2015-08-18 | Wisconsin Alumni Research Foundation | Dendritic cell targeting compositions and uses thereof |
US20090148535A1 (en) * | 2007-12-06 | 2009-06-11 | Minerva Biotechnologies Corporation | Method for treating cancer using interference rna |
KR101050401B1 (ko) * | 2008-05-09 | 2011-07-19 | 경북대학교 산학협력단 | 이중 방식 pet/mr 조영제 |
US8968705B2 (en) | 2008-08-22 | 2015-03-03 | Colorado School Of Mines | Gold/lanthanide nanoparticle conjugates and uses thereof |
CN106955360A (zh) | 2008-11-24 | 2017-07-18 | 西北大学 | 多价rna纳米颗粒组合物 |
US20120121717A1 (en) * | 2008-12-30 | 2012-05-17 | Xi'an Goldmag Nanobiotech Co. Ltd | DRUG-LOADED POLYSACCHARIDE-COATED GOLDMAG PARTICLES (DPGPs) AND ITS SYNTHESIS METHOD |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
WO2011008534A1 (en) * | 2009-06-30 | 2011-01-20 | Boston Scientific Scimed, Inc. | Implantable self-powered biodegradable medical device to treat or prevent reperfusion injury |
US20100331760A1 (en) * | 2009-06-30 | 2010-12-30 | Boston Scientific Scimed, Inc. | Biodegradable implant for treating or preventing reperfusion injury |
US20120277283A1 (en) * | 2009-08-04 | 2012-11-01 | Mirkin Chad A | Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications |
US20120244205A1 (en) * | 2009-08-25 | 2012-09-27 | The Regents Of The University Of California | Nanotechnological Delivery of Microbicides and Other Substances |
US8883471B2 (en) * | 2009-09-25 | 2014-11-11 | N3D Biosciences, Inc. | Materials for magnetizing cells and magnetic manipulation |
JP5866119B2 (ja) | 2009-10-30 | 2016-02-17 | ノースウェスタン ユニバーシティ | 鋳型ナノ複合体 |
US8565892B2 (en) | 2009-10-31 | 2013-10-22 | Qteris, Inc. | Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment |
WO2011075516A2 (en) | 2009-12-18 | 2011-06-23 | President And Fellows Of Harvard College | Active scaffolds for on-demand drug and cell delivery |
US9476812B2 (en) | 2010-04-21 | 2016-10-25 | Dna Electronics, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
US20110262989A1 (en) | 2010-04-21 | 2011-10-27 | Nanomr, Inc. | Isolating a target analyte from a body fluid |
US8841104B2 (en) | 2010-04-21 | 2014-09-23 | Nanomr, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
WO2011156711A1 (en) | 2010-06-10 | 2011-12-15 | Schobel Alexander M | Nanoparticle film delivery systems |
CA2802031C (en) | 2010-06-10 | 2015-05-12 | Midatech Limited | Peptide-carrying nanoparticles |
US8790704B2 (en) * | 2010-06-10 | 2014-07-29 | Monosol Rx, Llc | Combination peptide-nanoparticles and delivery systems incorporating same |
JP2013530981A (ja) * | 2010-06-25 | 2013-08-01 | アストン ユニバーシティ | 脂質動員特性を有する糖タンパク質およびその治療的使用 |
EP2621541A4 (en) * | 2010-09-29 | 2016-11-23 | Univ Alabama | MAGNETIC NANOPARTICLES WITH CONTROLLED SHAPE AS T1 CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING |
CN102243058B (zh) * | 2011-04-15 | 2013-03-27 | 中国船舶重工集团公司第七○二研究所 | 应变传感器灵敏度系数的标定装置和方法 |
KR101376675B1 (ko) * | 2011-04-19 | 2014-03-20 | 광주과학기술원 | 이미징 및 운반 이중기능 나노입자-기반 백신 전달체 |
CA2839865A1 (en) | 2011-05-19 | 2012-11-22 | University Of Central Florida Research Foundation, Inc. | Microbe detection via hybridizing magnetic relaxation nanosensors |
JP2014523914A (ja) | 2011-07-18 | 2014-09-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作された微生物標的化分子およびその使用 |
JP6077544B2 (ja) | 2011-09-07 | 2017-02-08 | ミダテック リミテッド | ナノ粒子−ペプチド組成物 |
CN103957943A (zh) | 2011-09-07 | 2014-07-30 | Mida科技有限公司 | 纳米颗粒肿瘤疫苗 |
ES2856091T3 (es) | 2011-09-14 | 2021-09-27 | Univ Northwestern | Nanoconjugados capaces de atravesar la barrera hematoencefálica |
WO2013056092A1 (en) | 2011-10-12 | 2013-04-18 | Case Western Reserve University | Multi-component nanochains |
US20130236507A1 (en) * | 2012-03-12 | 2013-09-12 | National Cheng Kung University | Method for treating cancer by using Fe-containing alloy particles |
US9884076B2 (en) | 2012-06-05 | 2018-02-06 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
CA2873274C (en) * | 2012-06-08 | 2021-06-01 | Ethris Gmbh | Pulmonary delivery of messenger rna |
EP3563859B1 (en) | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
US10000557B2 (en) | 2012-12-19 | 2018-06-19 | Dnae Group Holdings Limited | Methods for raising antibodies |
US9804069B2 (en) | 2012-12-19 | 2017-10-31 | Dnae Group Holdings Limited | Methods for degrading nucleic acid |
US9995742B2 (en) | 2012-12-19 | 2018-06-12 | Dnae Group Holdings Limited | Sample entry |
US9434940B2 (en) | 2012-12-19 | 2016-09-06 | Dna Electronics, Inc. | Methods for universal target capture |
WO2014100456A1 (en) * | 2012-12-19 | 2014-06-26 | Nanomr, Inc. | Target capture system |
US9551704B2 (en) | 2012-12-19 | 2017-01-24 | Dna Electronics, Inc. | Target detection |
US9599610B2 (en) | 2012-12-19 | 2017-03-21 | Dnae Group Holdings Limited | Target capture system |
WO2014100630A1 (en) * | 2012-12-20 | 2014-06-26 | The Board Of Trustees Of The University Of Alabama | Synthesis and surface functionalization of particles |
GB201301991D0 (en) | 2013-02-05 | 2013-03-20 | Midatech Ltd | Permeation enhanced active-carrying nanoparticles |
GB201302427D0 (en) | 2013-02-12 | 2013-03-27 | Midatech Ltd | Nanoparticle delivery compositions |
GB201303787D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticle peptide compositions |
GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
EP2976642A4 (en) | 2013-03-15 | 2016-09-21 | Harvard College | METHODS AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR CAPTURE OF A TARGET ENTITY |
CA2913155A1 (en) | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
ES2750608T3 (es) | 2013-07-25 | 2020-03-26 | Exicure Inc | Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico |
KR101536325B1 (ko) | 2013-10-16 | 2015-07-14 | 주식회사 지니스 | 전자기파를 이용한 암 온열치료용 감작제 조성물 및 이를 이용한 암 치료 방법 |
EP3083658B1 (en) | 2013-12-18 | 2019-05-08 | President and Fellows of Harvard College | Crp capture/detection of gram positive bacteria |
GB201401706D0 (en) | 2014-01-31 | 2014-03-19 | Midatech Ltd | Nanoparticle-insulin and insulin analogue compositions |
MX2016016507A (es) | 2014-06-12 | 2017-04-27 | Cedars Sinai Medical Center | Composiciones y metodos para tratar canceres. |
US9910035B1 (en) | 2014-07-16 | 2018-03-06 | Verily Life Sciences Llc | Polyvalent functionalized nanoparticle-based in vivo diagnostic system |
JP6878274B2 (ja) | 2014-10-03 | 2021-05-26 | シーダーズ−サイナイ・メディカル・センターCedars−Sinai Medical Center | 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム |
US20160122794A1 (en) * | 2014-10-30 | 2016-05-05 | Sightline Innovation Inc. | System, method and apparatus for pathogen detection |
AU2015349680A1 (en) | 2014-11-21 | 2017-06-08 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
EP3237016A1 (en) | 2014-12-23 | 2017-11-01 | Midatech Ltd | Nanoparticles and their use in cancer therapy |
GB2541166A (en) | 2015-07-24 | 2017-02-15 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
CN108289928A (zh) | 2015-08-06 | 2018-07-17 | 哈佛大学校长及研究员协会 | 改进的微生物-结合分子和其用途 |
WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS |
GB201701745D0 (en) | 2017-02-02 | 2017-03-22 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
US20190112731A1 (en) | 2017-10-12 | 2019-04-18 | Julianne Holloway | Manufacturing gradient materials using magnetically-assisted electrospinning |
EP3727351A4 (en) | 2017-12-20 | 2021-10-06 | Cedars-Sinai Medical Center | MODIFIED EXTRACELLULAR VESICLES FOR IMPROVED TISSUE DELIVERY |
GB201819430D0 (en) | 2018-11-29 | 2019-01-16 | Midatech Ltd | Therapeutic compounds, nanoparticles and uses thereof |
GB201820470D0 (en) | 2018-12-14 | 2019-01-30 | Midatech Ltd | Antifolate-carrying nanoparticles and their use in medicine |
GB201820471D0 (en) | 2018-12-14 | 2019-01-30 | Midatech Ltd | Nanoparticle-based therapy of inflammatory disorders |
EP3911746A1 (en) | 2019-01-14 | 2021-11-24 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity |
CN110470688B (zh) * | 2019-07-29 | 2021-07-13 | 华中农业大学 | 一种纳米螯合筛介导的低场核磁共振免疫传感器及其应用 |
CA3164781A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Methods of sequencing by synthesis using a consecutive labeling scheme |
IT202000001048A1 (it) * | 2020-01-21 | 2021-07-21 | Univ Degli Studi Padova | Nanoparticelle multifunzionali a base di nanoleghe metalliche per usi diagnostici e terapeutici. |
IT202100001049A1 (it) * | 2021-01-21 | 2022-07-21 | Univ Degli Studi Padova | Nanoparticelle multifunzionali a base di nanoleghe metalliche per usi diagnostici e terapeutici. |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US87204A (en) * | 1869-02-23 | Improved velocipede | ||
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4735796A (en) * | 1983-12-08 | 1988-04-05 | Gordon Robert T | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4662359A (en) * | 1983-08-12 | 1987-05-05 | Robert T. Gordon | Use of magnetic susceptibility probes in the treatment of cancer |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US4758429A (en) * | 1985-11-04 | 1988-07-19 | Gordon Robert T | Method for the treatment of arthritis and inflammatory joint diseases |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5260050A (en) * | 1988-09-29 | 1993-11-09 | Ranney David F | Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes |
GR1000686B (el) | 1989-11-16 | 1992-10-08 | Ortho Diagnostic Systems Inc | Μεθοδος παραγωγης ενος αντιδραστηριου κολλοειδους μεταλλου που περιεχει κολλοειδη τεμαχιδια μεταλλου με προκαθορισμενο μεγεθος. εθος. |
US6048897A (en) * | 1993-06-15 | 2000-04-11 | Brigham And Women's Hospital | Lipoxin compounds and their use in treating cell proliferative disorders |
US5521289A (en) * | 1994-07-29 | 1996-05-28 | Nanoprobes, Inc. | Small organometallic probes |
DK0783325T3 (da) * | 1994-09-27 | 2000-05-01 | Nycomed Imaging As | Kontrastmiddel |
CA2241183A1 (en) * | 1995-12-28 | 1997-07-10 | James R. Heath | Organically-functionalized monodisperse nanocrystals of metals |
AUPP008197A0 (en) * | 1997-10-29 | 1997-11-20 | Paragon Medical Limited | Improved targeted hysteresis hyperthermia as a method for treating diseased tissue |
EP1073902A2 (en) | 1998-04-20 | 2001-02-07 | University Of North Carolina At Chapel Hill | Nanometer particles containing a reactive monolayer |
DE19821968A1 (de) | 1998-05-18 | 1999-11-25 | Studiengesellschaft Kohle Mbh | Verfahren zur Modifizierung der Dispergiereigenschaften von metallorganisch-prästabilisierten bzw. -vorbehandelten Nanometallkolloiden |
US6645464B1 (en) * | 1998-07-30 | 2003-11-11 | James F. Hainfeld | Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy |
EP1031354A3 (en) * | 1999-01-19 | 2003-02-05 | Rohm And Haas Company | Polymeric MRI Contrast agents |
US6254662B1 (en) | 1999-07-26 | 2001-07-03 | International Business Machines Corporation | Chemical synthesis of monodisperse and magnetic alloy nanocrystal containing thin films |
WO2001019405A2 (de) | 1999-09-14 | 2001-03-22 | Biomedical Apherese Systeme Gmbh | Magnetische nanoteilchen mit biochemischer wirksamkeit und verfahren zu ihrer herstellung sowie ihre verwendung |
AU4305101A (en) | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
US6773823B2 (en) * | 2000-04-07 | 2004-08-10 | University Of New Orleans Research And Technology Foundation, Inc. | Sequential synthesis of core-shell nanoparticles using reverse micelles |
GB0025414D0 (en) * | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
US7132275B2 (en) | 2001-05-14 | 2006-11-07 | The John Hopkins University | Multifunctional magnetic nanowires |
AU2002320058A1 (en) | 2001-06-06 | 2002-12-16 | The General Hspital Corporation | Magnetic-nanoparticle conjugates and methods of use |
AU2002317095A1 (en) | 2001-07-03 | 2003-01-21 | Governors Of The University Of Alberta | Magnetic nanoparticles for bioseparation application and methods for producing same |
WO2003026481A2 (en) * | 2001-09-26 | 2003-04-03 | Rice University | Optically-absorbing nanoparticles for enhanced tissue repair |
FR2832671B1 (fr) * | 2001-11-23 | 2004-01-16 | Michelin Soc Tech | Disque de roue automobile, notamment pour vehicule de tourisme |
US7186398B2 (en) * | 2002-02-22 | 2007-03-06 | Purdue Research Foundation | Fe/Au nanoparticles and methods |
WO2003086660A1 (en) | 2002-04-09 | 2003-10-23 | The Government Of The United States Of America As Represented By The Secretary Of The Navy | Magnetic nanoparticles having passivated metallic cores |
CN1753724A (zh) | 2002-09-18 | 2006-03-29 | 得克萨斯州立大学董事会 | 肽介导的金属和磁性材料的合成 |
-
2003
- 2003-06-09 GB GBGB0313259.4A patent/GB0313259D0/en not_active Ceased
-
2004
- 2004-06-07 ES ES10009913T patent/ES2401957T3/es not_active Expired - Lifetime
- 2004-06-07 EP EP10009913A patent/EP2277548B1/en not_active Expired - Lifetime
- 2004-06-07 US US10/559,957 patent/US8557607B2/en not_active Expired - Fee Related
- 2004-06-07 JP JP2006516378A patent/JP5008977B2/ja not_active Expired - Fee Related
- 2004-06-07 AU AU2004244811A patent/AU2004244811B9/en not_active Ceased
- 2004-06-07 ES ES04736221T patent/ES2355728T3/es not_active Expired - Lifetime
- 2004-06-07 ES ES12167788.4T patent/ES2441235T3/es not_active Expired - Lifetime
- 2004-06-07 WO PCT/GB2004/002408 patent/WO2004108165A2/en active Search and Examination
- 2004-06-07 EP EP12167788.4A patent/EP2486944B1/en not_active Expired - Lifetime
- 2004-06-07 EP EP04736221A patent/EP1631318B1/en not_active Expired - Lifetime
- 2004-06-07 AT AT04736221T patent/ATE487496T1/de active
- 2004-06-07 DE DE602004030003T patent/DE602004030003D1/de not_active Expired - Lifetime
- 2004-06-07 DK DK04736221.5T patent/DK1631318T3/da active
- 2004-06-07 CA CA2528460A patent/CA2528460C/en not_active Expired - Fee Related
-
2012
- 2012-09-13 HK HK12109012.1A patent/HK1168051A1/xx not_active IP Right Cessation
-
2013
- 2013-10-02 US US14/044,113 patent/US20140107738A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE487496T1 (de) | 2010-11-15 |
US20060233712A1 (en) | 2006-10-19 |
EP1631318A2 (en) | 2006-03-08 |
ES2441235T3 (es) | 2014-02-03 |
EP2486944A1 (en) | 2012-08-15 |
EP1631318B1 (en) | 2010-11-10 |
AU2004244811B9 (en) | 2008-04-24 |
AU2004244811B2 (en) | 2008-02-07 |
DK1631318T3 (da) | 2011-02-21 |
WO2004108165A2 (en) | 2004-12-16 |
ES2401957T3 (es) | 2013-04-25 |
US8557607B2 (en) | 2013-10-15 |
DE602004030003D1 (de) | 2010-12-23 |
JP5008977B2 (ja) | 2012-08-22 |
AU2004244811A1 (en) | 2004-12-16 |
CA2528460A1 (en) | 2004-12-16 |
CA2528460C (en) | 2012-10-30 |
ES2355728T3 (es) | 2011-03-30 |
EP2277548A3 (en) | 2011-04-27 |
GB0313259D0 (en) | 2003-07-16 |
EP2277548A2 (en) | 2011-01-26 |
EP2277548B1 (en) | 2013-01-16 |
EP2486944B1 (en) | 2013-12-04 |
US20140107738A1 (en) | 2014-04-17 |
JP2006527245A (ja) | 2006-11-30 |
WO2004108165A3 (en) | 2005-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1168051A1 (en) | Magnetic nanoparticles | |
AU9406801A (en) | Nanoparticles | |
IL247486B (en) | A composition comprising nanoparticles comprising docetaxel, albumin and citrate, uses thereof, a method for it's preparation and a sealed vial and a kit comprising the composition | |
EP1801182A4 (en) | BODY EMITTING WITH FLUORESCENT LIGHT EMITTED, METHOD FOR THE PRODUCTION THEREOF, AND A FABRIC OR SUBSTANCE CONTAINING SUCH LIGHT EMITTING BODY | |
ZA200608451B (en) | Seeded boehmite particulate material and methods for forming same | |
WO2008082698A3 (en) | Medical devices and methods of making the same | |
EP1780781A4 (en) | PROCESS FOR PRODUCING SILICON DISK AND SILICON DISC PRODUCED THEREBY | |
WO2006034455A3 (en) | Polipeptide compounds for inhibiting angiogenesis and tumor growth | |
WO2008030862A3 (en) | Magnetic particles and methods of making and using the same | |
WO2006116369A3 (en) | Method for treating dementia or alzheimer's disease with a cd20 antibody | |
IL180954A0 (en) | Nanoparticles and method for the production thereof | |
AP2006003778A0 (en) | 5,6-Dialkyl-7-amino-triazolopyrimidines, method for their production, their use for controlling pat hogenic fungi and agents containing said compounds | |
TW200612910A (en) | Medicaments comprising carbonyl compounds, and the use thereof | |
WO2008106503A3 (en) | Discrete size and shape specific pharmaceutical organic nanoparticles | |
ATE482299T1 (de) | Sputtern von ag-basislegierungszielmaterial und verfahren zur herstellung davon | |
GB2445638A (en) | Granular solid wax particle | |
TW200735137A (en) | Composite magnetic sheet and production method thereof | |
EP1559765A3 (en) | Method of manufacturing a semiconductor nanoparticle | |
TWI347925B (en) | Metal fine particle, composition containing the same, and production method for the same | |
WO2006060171A3 (en) | Methods and compositions related to phage-nanoparticle assemblies | |
ATE512238T1 (de) | Materialsystem und verfahren zur dessen herstellung | |
WO2007028645A3 (de) | Antimikrobielles medizintechnisches produkt, verfahren zu seiner herstellung und verwendung | |
WO2002064666A3 (de) | Polyphosphazen-haltige substrate als matrize und mit mikrostrukturierter oberfläche | |
GB0319797D0 (en) | Particle size reduction of poorly soluble drugs | |
TW200514144A (en) | Fabrication of nanowires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CORR | Corrigendum |
Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF 20140321: (72) PENADES, SOLEDAD MARTIN-LOMAS, M MARTINES DE LA FUENTE, JESUS. RADEMACHER, THOMAS WILLIAM |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180607 |